Precision Biosciences Inc (NASDAQ:DTIL) has a beta value of 1.46 and has seen 7.48 million shares traded in the recent trading session. The company, currently valued at $47.45M, closed the recent trade at $4.28 per share which meant it lost -$0.29 on the day or -6.35% during that session. The DTIL stock price is -159.11% off its 52-week high price of $11.09 and 15.65% above the 52-week low of $3.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 99800.0 shares traded. The 3-month trading volume is 129.60K shares.
The consensus among analysts is that Precision Biosciences Inc (DTIL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.2.
Precision Biosciences Inc (NASDAQ:DTIL) trade information
Sporting -6.35% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the DTIL stock price touched $4.28 or saw a rise of 14.23%. Year-to-date, Precision Biosciences Inc shares have moved -54.47%, while the 5-day performance has seen it change -12.65%. Over the past 30 days, the shares of Precision Biosciences Inc (NASDAQ:DTIL) have changed -6.55%. Short interest in the company has seen 0.57 million shares shorted with days to cover at 7.14.
Wall Street analysts have a consensus price target for the stock at $15.5, which means that the shares’ value could jump 72.39% from the levels at last check today.. The projected low price target is $1.0 while the price target rests at a high of $30.0. In that case, then, we find that the latest price level in today’s session is -600.93% off the targeted high while a plunge would see the stock lose 76.64% from the levels at last check today..
Precision Biosciences Inc (DTIL) estimates and forecasts
The company’s shares have lost -6.96% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -77.80%.
3 analysts offering their estimates for the company have set an average revenue estimate of 6.27M for the current quarter. 3 have an estimated revenue figure of 5.37M for the next ending quarter. Year-ago sales stood 49.9M and 576k respectively for this quarter and the next, and analysts expect sales will shrink by -87.44% for the current quarter and -77.80% for the next.
DTIL Dividends
Precision Biosciences Inc is expected to release its next earnings report on 2025-May-15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Precision Biosciences Inc (NASDAQ:DTIL)’s Major holders
Insiders own 11.01% of the company shares, while shares held by institutions stand at 43.37% with a share float percentage of 48.73%. Investors are also buoyed by the number of investors in a company, with Precision Biosciences Inc having a total of 63.0 institutions that hold shares in the company. The top two institutional holders are JANUS HENDERSON GROUP PLC with over 0.63 million shares worth more than $6.18 million. As of 2024-06-30, JANUS HENDERSON GROUP PLC held 9.0879% of shares outstanding.
The other major institutional holder is TANG CAPITAL MANAGEMENT LLC, with the holding of over 0.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.07 million and represent 8.9473% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 1.58% shares in the company for having 174.93 shares of worth $0.75 million while later fund manager owns 74.66 shares of worth $0.32 million as of Mar 31, 2025 , which makes it owner of about 0.67% of company’s outstanding stock.
